Latest Breaking News On - Christian lizak - Page 4 : comparemela.com

Philogen S.p.A.: Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS (i) Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs - (ii) OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce a publication describing the development and the in vivo characterization of OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation. The paper entitled An Ultra-High Affinity Small Organic Ligand of Fibroblast Activation Protein for Tumor Targeting Applications was published in the peer-reviewed journal

Christian lizakDario neriEmanuele pucaItalian stock exchangeBusiness developmentUltra high affinity small organic ligandFibroblast activation proteinTumor targetingActivation proteinChief executive officerItalian stockInvestor relationsடாரியோ நெறிஇத்தாலிய ஸ்டாக் பரிமாற்றம்வணிக வளர்ச்சிஃபைப்ரோபிளாஸ்ட் செயல்படுத்தல் ப்ரோடீந்